The broader context weighs on the stock — Cipla is down 14.36 per cent year-to-date and 17.17 per cent over the past year, significantly underperforming the Nifty 50, which has lost 1.21 per cent in the same period
Cipla slips despite FDA nod for generic Ventolin; Morgan Stanley stays cautious
The Hindu Business Line·The Hindu Business Line··1 min readLimited
T
Continue reading on The Hindu Business Line
This article was sourced from The Hindu Business Line's RSS feed. Visit the original for the complete story.
Limited free access — this source offers metered access before requiring a subscription.